<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6510">
  <stage>Registered</stage>
  <submitdate>18/10/2016</submitdate>
  <approvaldate>18/10/2016</approvaldate>
  <nctid>NCT02939183</nctid>
  <trial_identification>
    <studytitle>Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma</studytitle>
    <scientifictitle>(INTREPID-1) A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Oprozomib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma</scientifictitle>
    <utrn />
    <trialacronym>INTREPID-1</trialacronym>
    <secondaryid>20160104</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Relapsed or Refractory Multiple Myeloma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Oprozomib formulation 1
Treatment: drugs - Oprozomib formulation 2
Treatment: drugs - Dexamethasone
Treatment: drugs - Pomalidomide

Experimental: Part 1 Arm 1 - Oprozomib formulation 1 plus dexamethasone

Experimental: Part 1 Arm 2 - Oprozomib formulation 2 plus dexamethasone

Experimental: Part 2 Arm 1 - Oprozomib formulation 1 plus pomalidomide and dexamethasone

Experimental: Part 2 Arm 2 - Oprozomib formulation 2 plus pomalidomide and dexamethasone


Treatment: drugs: Oprozomib formulation 1
Immediate Release (IR) Formulation

Treatment: drugs: Oprozomib formulation 2
Gastro-Retentive (GR) Formulation

Treatment: drugs: Dexamethasone
Dexamethasone

Treatment: drugs: Pomalidomide
Pomalidomide

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Determine the maximum tolerated dose for each formulation of oprozomib in combination with pomalidomide and dexamethasone</outcome>
      <timepoint>The primary analysis will be based on subject data collected up to 2 months from the date of last subject enrollment</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria

          -  Subject must have a pathologically documented, definitively diagnosed, multiple
             myeloma relapsed, or refractory progressive disease after at least 2 lines of therapy
             for multiple myeloma. Prior therapeutic treatment or regimens must include a
             proteasome inhibitor and lenalidomide.

          -  Subject must be willing and able to undergo bone marrow aspirate per protocol (with or
             without bone marrow biopsy per institutional guidelines).

          -  Measurable disease (assessed within 28 days prior to day 1)

          -  Eastern Cooperative Oncology Group (ECOG) performance status of &gt;= 2.

          -  Other Inclusion Criteria May Apply</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>100</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion Criteria

          -  Currently receiving treatment in another investigational device or drug study, or less
             than 28 days since ending treatment on another investigational device or drug study.

          -  Previously received an allogeneic stem cell transplant and the occurrence of one or
             more of the following: received the transplant within 6 months prior to study day
             1;received immunosuppressive therapy within the last 3 months prior to study day
             1;having signs or symptoms of acute or chronic graft-versus-host disease.

          -  Autologous stem cell transplant &lt; 90 days prior to study day 1.

          -  Multiple myeloma with IgM subtype.

          -  POEMs syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and
             skin changes).

          -  Plasma cell leukemia (&gt; 2.0 X109/L circulating plasma cells by standard differential).

          -  Waldenstrom's macroglobulinemia.

          -  Other Exclusion Criteria May Apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>17/01/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>64</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>29/04/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Research Site - Murdoch</hospital>
    <hospital>Research Site - Nedlands</hospital>
    <postcode>6150 - Murdoch</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Amgen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>A study evaluating two new formulations of oprozomib plus pomalidomide and dexamethasone in
      patients with relapsed refractory multiple myeloma.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02939183</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>MD</name>
      <address>Amgen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Amgen Call Center</name>
      <address />
      <phone>866-572-6436</phone>
      <fax />
      <email>medinfo@amgen.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>